Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.

Antigens, CD20 B-Lymphocytes B7-H1 Antigen / genetics Biomarkers, Tumor Breast Neoplasms / drug therapy Female Humans Inflammatory Breast Neoplasms Lymphocytes, Tumor-Infiltrating Prognosis
CD20 Immuno-oncology Inflammatory breast cancer Locally advanced breast cancer PD-L1 Patient outcomes Tumor-infiltrating lymphocytes pCR

Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 04 06 2021
accepted: 06 09 2021
pubmed: 21 9 2021
medline: 3 11 2021
entrez: 20 9 2021
Statut: ppublish

Résumé

This study evaluated epidemiologic and immune factors associated with pathologic complete response (pCR), breast cancer-specific survival (BCSS) and disease-free survival (DFS) outcomes in inflammatory (IBC) and locally advanced breast cancer (LABC) patients. Tumor-infiltrating lymphocytes (TILs) and CD20 IBC and LABC display similar levels of TILs, CD20 CD20

Identifiants

DOI: 10.1007/s10549-021-06391-5 PMID: 34542773 PMC: PMC8603784
pubmed: 34542773
doi: 10.1007/s10549-021-06391-5
pii: 10.1007/s10549-021-06391-5
pmc: PMC8603784
mid: NIHMS1754362
doi:

Substances chimiques

Antigens, CD20 0
B7-H1 Antigen 0
Biomarkers, Tumor 0
CD274 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

477-489

Subventions

Organisme : Foundation for the National Institutes of Health
ID : CA163890
Organisme : NCI NIH HHS
ID : P30 CA118100
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA163890
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA023108
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM121176
Pays : United States
Organisme : Foundation for the National Institutes of Health
ID : CA194496
Organisme : NCI NIH HHS
ID : R01 CA224605
Pays : United States
Organisme : International Union Against Cancer
ID : ICR/09/0443
Organisme : GlaxoSmithKline
ID : No number
Organisme : NCI NIH HHS
ID : R01 CA194496
Pays : United States
Organisme : Foundation for the National Institutes of Health
ID : R01CA224605

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
PLoS One. 2016 Oct 19;11(10):e0164841
pubmed: 27760178
J Cancer Res Clin Oncol. 2017 Jan;143(1):161-168
pubmed: 27704268
BMC Cancer. 2018 Jul 5;18(1):713
pubmed: 29976157
Breast Cancer Res Treat. 2016 Aug;158(3):485-95
pubmed: 27393622
Ann Oncol. 2014 Jun;25(6):1143-51
pubmed: 24669011
Ann Oncol. 2011 Mar;22(3):515-523
pubmed: 20603440
J Natl Cancer Inst. 2013 Sep 18;105(18):1373-84
pubmed: 24046390
Breast Cancer Res Treat. 2019 Nov;178(1):17-33
pubmed: 31359214
Breast Cancer Res Treat. 2019 Jul;176(1):217-226
pubmed: 30972613
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Oncotarget. 2015 May 30;6(15):13506-19
pubmed: 25940795
Future Oncol. 2021 Apr;17(10):1209-1218
pubmed: 33289433
Lancet Oncol. 2015 Nov;16(15):e568-e576
pubmed: 26545845
Br J Surg. 2021 Jun 22;108(6):622-631
pubmed: 33963374
J Clin Oncol. 2010 Apr 20;28(12):2015-23
pubmed: 20308671
Am J Clin Pathol. 2018 Feb 17;149(3):253-261
pubmed: 29425258
Oncologist. 2007 Aug;12(8):904-12
pubmed: 17766649
J Clin Oncol. 2004 Oct 15;22(20):4067-74
pubmed: 15483018
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
Cancer Causes Control. 2016 Mar;27(3):359-66
pubmed: 26797453
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811
pubmed: 29873743
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Breast Cancer Res. 2019 Feb 18;21(1):28
pubmed: 30777104
Cancer Manag Res. 2020 Dec 03;12:12447-12455
pubmed: 33299352
Breast Cancer Res Treat. 2017 Apr;162(2):365-374
pubmed: 28138891
Cancer. 2011 May 1;117(9):1819-26
pubmed: 21509759
Breast Cancer Res Treat. 2012 Jan;131(2):437-44
pubmed: 21360074
Clin Breast Cancer. 2015 Feb;15(1):1-7
pubmed: 25034439
Cancer Immunol Res. 2019 Jun;7(6):1025-1035
pubmed: 31043414
Breast Cancer Res Treat. 2012 Apr;132(2):545-53
pubmed: 21671016
J Clin Oncol. 2010 Jan 1;28(1):83-91
pubmed: 19901111
PLoS One. 2015 Jul 24;10(7):e0132710
pubmed: 26207636
Breast Cancer Res Treat. 2012 Aug;134(3):1257-68
pubmed: 22733221
J Clin Oncol. 2011 Mar 10;29(8):1014-21
pubmed: 21220618
Clin Breast Cancer. 2004 Feb;4(6):415-9
pubmed: 15023242
Breast Cancer Res. 2019 Dec 26;21(1):151
pubmed: 31878981
J Natl Cancer Inst. 2005 Jul 6;97(13):966-75
pubmed: 15998949
Breast J. 2009 Jul-Aug;15(4):432-4
pubmed: 19601951
Lancet. 2010 Jan 30;375(9712):377-84
pubmed: 20113825
Oncotarget. 2017 Jul 31;8(39):66019-66032
pubmed: 29029489
Breast Cancer Res Treat. 2018 Sep;171(2):273-282
pubmed: 29858752
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Obes Res. 1998 Sep;6 Suppl 2:51S-209S
pubmed: 9813653
Mol Clin Oncol. 2019 Feb;10(2):223-230
pubmed: 30680198
Nat Rev Cancer. 2018 Aug;18(8):485-499
pubmed: 29703913
Cancer. 2006 Mar 1;106(5):1000-6
pubmed: 16444747
Lancet Oncol. 2012 Apr;13(4):375-84
pubmed: 22377126

Auteurs

Hugo Arias-Pulido (H)

Department of Microbiology, and Immunology and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 621 Rubin Building-HB7936, 1 Medical Center Drive, Lebanon, NH, 03756, USA. hugo.ariaspulido@dartmouth.edu.
ORCID: 0000-0003-4941-1110

Ashley Marie Cimino-Mathews (AM)

Departments of Pathology and Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Nabila Chaher (N)

Department of Pathology, Centre Pierre et Marie Curie, EHS Salim Zemirli et Faculté de Médecine d'Alger, Université Alger 1, Algiers, Algeria.

Clifford Ray Qualls (CR)

Department of Mathematics and Statistics, University of New Mexico, Albuquerque, NM, USA.

Nancy Joste (N)

Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.

Cecile Colpaert (C)

Department of Pathology, AZ Turnhout/UZ, Leuven, Belgium.

Jonathan Douglas Marotti (JD)

Department of Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.

Mary Dickinson Chamberlin (MD)

Department of Medical Oncology, and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.

Maxwell Gabriel Foisey (MG)

Department of Microbiology, and Immunology and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 621 Rubin Building-HB7936, 1 Medical Center Drive, Lebanon, NH, 03756, USA.
Biomedical Sciences Graduate Training Program, University of California, San Francisco, CA, 94143, USA.

Eric Robert Prossnitz (ER)

Division of Molecular Medicine, Department of Internal Medicine, Autophagy, Inflammation and Metabolism Center of Biomedical Research Excellence, University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.

Leisha Ann Emens (LA)

University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.

Steven Fiering (S)

Department of Microbiology, and Immunology and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 621 Rubin Building-HB7936, 1 Medical Center Drive, Lebanon, NH, 03756, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes B › Antigènes CD20 › Differential effects of CD20+ B cells and...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes B › Differential effects of CD20+ B cells and...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › Differential effects of CD20+ B cells and...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Differential effects of CD20+ B cells and...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Differential effects of CD20+ B cells and...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Differential effects of CD20+ B cells and...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Cancers du sein inflammatoires › Differential effects of CD20+ B cells and...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes TIL › Differential effects of CD20+ B cells and...
questionsmedicales.fr › Diagnostic › Pronostic › Differential effects of CD20+ B cells and...